Entos Pharmaceuticals
Entos Pharmaceuticals is a clinical-stage biotech developing genetic medicines via its Fusogenix PLV non-viral delivery platform, leveraging FAST fusion proteins to deliver RNA, DNA, and gene editing payloads directly into cells across metabolic, ocular, vaccine, and rare disease indications.
- Company typePrivate
- Founded2017
- HeadquartersEdmonton, Canada
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Entos Pharmaceuticals does
Entos Pharmaceuticals is a clinical-stage biotech company founded in Edmonton, Canada, that develops genetic medicines using its proprietary Fusogenix PLV (Proteo-Lipid Vehicle) drug delivery platform. The platform is built on FAST (Fusion Associated Small Transmembrane) proteins, which the company's scientific founder Roy Duncan discovered at Dalhousie University; these proteins catalyze direct membrane fusion between nanoparticles and target cell plasma membranes, enabling cytoplasmic delivery of RNA, DNA, and gene editing payloads while bypassing endosomal entrapment and avoiding the liver tropism and immunogenicity constraints of conventional lipid nanoparticle systems. The company complements the core biology with two proprietary technology layers: Fusogenix AIM (Advanced Interactive Modules) for precision cell- and tissue-specific targeting, and FOCUS-AI, an in-house AI workflow trained on years of iterative formulation data that designs bespoke PLV compositions for different indications.
Entos's clinical and preclinical pipeline spans three core programs: ENTLEP001, a leptin-encoding gene therapy for obesity and congenital generalized lipodystrophy that is advancing toward IND-enabling activities; ENTSTAR001, an ocular gene therapy delivering the full-length ABCA4 gene for Stargardt disease; and ENTVAX002, a plasmid DNA COVID-19 booster vaccine currently in a Phase I/II clinical trial (NCT06436911). The platform also underpins lung-targeted formulations and rare neuromuscular programs such as an L-CMD gene therapy collaboration with the L-CMD Research Foundation. Specialized formulations include Systemic, Ocular, Lung, and Vaccine PLV variants.
The company operates a partnership- and licensing-driven business model with no product revenue. It monetizes the platform through co-development agreements, out-licensing of pipeline assets, and non-dilutive grant funding, with Eli Lilly as a flagship research and collaboration partner and the Bill & Melinda Gates Foundation listed among its valued partners. CureDuchenne Ventures has invested to support a Duchenne muscular dystrophy program, and the California Institute for Regenerative Medicine provided a $4M grant for ENTLEP001 IND-enabling work. Entos has a wholly-owned US spinout, Aegis Life Inc., dedicated to vaccine commercialization, and operates GMP manufacturing in Carlsbad, California, alongside its Edmonton, San Diego, and London offices.
Entos Pharmaceuticals firmographics
Firmographics- Name
- Entos Pharmaceuticals
- Legal name
- Entos Pharmaceuticals
- Website
- https://entospharma.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Entos Pharmaceuticals is a clinical-stage biotech developing genetic medicines via its Fusogenix PLV non-viral delivery platform, leveraging FAST fusion proteins to deliver RNA, DNA, and gene editing payloads directly into cells across metabolic, ocular, vaccine, and rare disease indications.
- Ownership category
- akta.pro rank
Entos Pharmaceuticals industry classification
Industry- Product category
- Genetic Medicine Drug Delivery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)
- akta.pro secondary industries
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI), Neurology/CNS Gene Therapies (HLAAACAH), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where Entos Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Edmonton
- HQ country
- Canada
- HQ region
- North America
Offices5 records
Markets served
Entos Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Genetic Medicine Development & Licensing: Entos develops proprietary genetic medicine pipeline assets using its Fusogenix PLV platform and seeks to partner or license programs with large pharmaceutical companies for co-development and commercialization. Revenue would be generated through upfront payments, milestone payments, and royalties on net sales.
- Research Collaborations & Strategic Partnerships: Co-development agreements with pharmaceutical partners and research foundations (e.g., Eli Lilly, L-CMD Research Foundation) providing research funding, development milestones, and potential commercialization rights.
- Grant Funding: Non-dilutive funding from government and non-profit organizations such as the California Institute for Regenerative Medicine ($4M grant for ENTLEP001 IND-enabling activities).
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Entos Pharmaceuticals product offering
Product offeringCore offering
Entos Pharmaceuticals develops and licenses the Fusogenix PLV drug delivery platform — a fusion-protein-based non-viral system for delivering RNA, DNA, and gene editing payloads directly into the cytoplasm of target cells. The company advances a clinical-stage pipeline of genetic medicines including a leptin gene therapy (ENTLEP001) for obesity and congenital generalized lipodystrophy, an ABCA4 gene therapy (ENTSTAR001) for Stargardt disease, and a COVID-19 booster DNA vaccine (ENTVAX002) currently in Phase I/II trials.
Product overview
Entos Pharmaceuticals is a biotech company developing genetic medicines using its proprietary Fusogenix PLV (Proteoliposome Vesicle) platform. The platform utilizes FAST (Fusion Associated Small Transmembrane) proteins to enable direct fusion delivery of nucleic acids into cells, bypassing endocytosis. The core products include ENTLEP001 (gene therapy for obesity/metabolic disease), ENTSTAR001 (gene therapy for Stargardt disease), and ENTVAX002 (COVID-19 booster vaccine in phase I/II trials). The platform includes specialized formulations for systemic, ocular, lung, and vaccine applications, enhanced by AI-powered FOCUS-AI formulation design and Fusogenix AIM precision targeting technology.
Differentiator
Problem solved
Functional benefit
Brands
- Fusogenix PLV: A fusion-powered drug delivery platform for RNA and DNA genetic medicines, utilizing FAST (Fusion Associated Small Transmembrane) proteins for direct cell membrane fusion delivery.
Products and services
- Fusogenix PLV Platform
Quantifiable outcome
- ENTVAX002 COVID-19 booster vaccine demonstrated longer durability, stronger T-cell response, and fridge-stable formulation in Phase I/II clinical trial.
- +2 more outcomes
Companies that use Entos Pharmaceuticals
Customer profileSegments4 records
Ideal customer profiles3 records
Entos Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Entos Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and flagship.
- L-CMD Research FoundationcoreEntos Pharmaceuticals and the L-CMD Research Foundation are collaborating to develop a curative gene therapy for LMNA-related congenital muscular dystrophy (L-CMD), a fatal condition affecting at least 200 children worldwide with no existing treatments. The partnership leverages Entos's Fusogenix PLV non-viral delivery platform with novel gene editing approaches and muscle-targeted formulations to create redosable, potentially curative therapies. The organizations aim to utilize emerging FDA regulatory pathways to accelerate access for patients.
- Eli Lilly and CompanyflagshipEli Lilly and Entos Pharmaceuticals entered a research and collaboration agreement focused on the Fusogenix PLV platform technology. Lilly is listed as a valued partner on Entos's website and has invested through its corporate venture arm, representing a major strategic pharma partnership.
- Aegis Life Inc.coreAegis Life Inc. is a US-based spinout company launched by Entos to support its global vaccine commercialization strategy. Aegis Life received investment to continue development of DNA-encoded therapeutic antibodies against infectious diseases using the Fusogenix PLV platform. Aegis Life operates as a separate entity leveraging Entos technology.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Entos Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Acuitas Therapeutics: Acuitas is a Canadian clinical-stage company developing lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, including mRNA vaccines and gene therapies. It is a direct competitor in non-viral nucleic acid delivery and supplies LNPs used in approved COVID-19 vaccines.
- Verve Therapeutics: Verve Therapeutics develops in vivo gene editing therapies for cardiovascular disease using both LNP delivery and base editing technologies. Comparable as a clinical-stage platform company using non-viral delivery for systemic genetic medicines targeting metabolic disease.
- Arcturus Therapeutics: Arcturus develops lipid-mediated delivery systems for mRNA and gene editing therapeutics, including LUNAR® technology targeting liver and non-liver tissues. Comparable as a clinical-stage platform company with proprietary non-viral delivery and pipeline assets across rare disease and infectious disease.
- Generation Bio: Generation Bio develops non-viral lipid nanoparticle-based gene therapies for rare diseases including hemophilia A. Comparable as a clinical-stage non-viral gene therapy company targeting rare genetic diseases with redosable delivery technology.
Emerging players
- Bio-Path Holdings: Bio-Path develops Pbi-shRNA and neutral lipid delivery technology (DNABLOC) for nucleic acid therapeutics. Comparable as a clinical-stage company using proprietary lipid-based delivery for systemic gene therapy and rare disease applications.
- Intravacc: Intravacc develops vaccine delivery technologies and novel adjuvants including non-viral platforms. Comparable as an emerging platform player in vaccine delivery with overlapping interest in nucleic acid-based vaccine formulations.
- Precision BioSciences: Precision BioSciences develops in vivo and ex vivo gene editing therapies using ARCUS, a proprietary homing endonuclease platform. Comparable as an emerging genetic medicines platform pursuing non-viral delivery and rare disease indications.
- Cibus Bio (previously eTheRNA): Cibus Bio is an early-stage mRNA-based genetic medicines company focused on non-viral delivery of mRNA immunotherapies and vaccines. Comparable as an emerging player in the non-viral nucleic acid delivery space with overlapping therapeutic indications.
Broad incumbents
- Moderna: Moderna is the largest mRNA therapeutics company, with approved vaccines and a deep pipeline including gene therapies (e.g., via its acquisition of OriCiro Genomics). It is a broad incumbent competing in nucleic acid delivery across vaccines, rare disease, and oncology.
- BioNTech: BioNTech is a leading mRNA therapeutics and vaccine company with multiple approved products and a broad pipeline spanning oncology, infectious disease, and rare disease. It is a broad incumbent developing its own proprietary non-viral delivery innovations and competing in the same nucleic acid delivery space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Entos Pharmaceuticals social profiles
Digital presenceEntos Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Entos Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles14 records
Entos Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries1 record
Entos Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Entos Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Entos Pharmaceuticals
What does Entos Pharmaceuticals do?
Entos Pharmaceuticals develops and licenses the Fusogenix PLV drug delivery platform — a fusion-protein-based non-viral system for delivering RNA, DNA, and gene editing payloads directly into the cytoplasm of target cells. The company advances a clinical-stage pipeline of genetic medicines including a leptin gene therapy (ENTLEP001) for obesity and congenital generalized lipodystrophy, an ABCA4 gene therapy (ENTSTAR001) for Stargardt disease, and a COVID-19 booster DNA vaccine (ENTVAX002) currently in Phase I/II trials.
Is Entos Pharmaceuticals a public or private company?
Entos Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Entos Pharmaceuticals founded?
Entos Pharmaceuticals was founded in 2017. It employs 51 to 100 people.
Where is Entos Pharmaceuticals based?
Entos Pharmaceuticals is headquartered in Edmonton, Canada, in the North America region.
How does Entos Pharmaceuticals make money?
Three revenue lines are on record. Genetic Medicine Development & Licensing is the primary driver. The others are research Collaborations & Strategic Partnerships and grant Funding.
Who are Entos Pharmaceuticals's main competitors?
Direct peers on record are Acuitas Therapeutics, Verve Therapeutics, Arcturus Therapeutics and Generation Bio. Emerging players are Bio-Path Holdings, Intravacc, Precision BioSciences and Cibus Bio (previously eTheRNA). Broad incumbents are Moderna and BioNTech.
Does Entos Pharmaceuticals have an API?
No public API is recorded for Entos Pharmaceuticals.
What industry is Entos Pharmaceuticals in?
Entos Pharmaceuticals's product category is Genetic Medicine Drug Delivery Platform. Its primary akta.pro industry code is HLAAACAL, Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery), with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.